The microtubule-targeting drugs paclitaxel and docetaxel are widely used in the treatment of breast cancer. Unfortunately, single-agent trials indicate that only 30-50% of patients respond to these taxane-based therapies. The goals of this application are to study a recently described pathway affecting sensitivity to these agents and evaluate the impact of alterations in this pathway in human breast cancer. Intensive studies over the past 20 years have elucidated multiple mechanisms of resistance to taxanes. Recent interest has focused on the role of changes in mitotic checkpoints as determinants of taxane sensitivity. Chfr encodes a 72 kDa polypeptide involved in a novel mitotic checkpoint pathway. Chfr expression is frequently down-regulated in many human cancers. Additionally, Chfr downregulation is associated with enhanced taxane sensitivity. These data raise the possibility that Chfr downregulation not only contributes to tumorigenesis, but also conveys increased sensitivity of breast cancers to taxanebased therapies. We recently generated Chfr-deficient mice and directly demonstrated that Chfr is required for mitotic checkpoint control, maintenance of genomic stability and tumor suppression in mice. Based on these data, we hypothesize that Chfr acts as a tumor suppressor in human breast cancer. Further, we postulate that breast cancers with Chfr downregulation will be more likely to respond to taxane-containing therapy. To test these hypotheses, we propose to: 1) study the mechanism by which Chfr regulates the mitotic checkpoint;2) examine whether Chfr downregulation contributes to breast cancer development in mice;3) determine whether Chfr downregulation increases paclitaxel sensitivity in vitro and in mouse models;4) explore the relationship between Chfr expression and paclitaxel sensitivity in clinical breast cancer specimens. These studies rely on the Breast Biospecimens and Biostatistics Cores. In summary, studies outlined here will elucidate the precise molecular role of CHFR in the control of mitotic progression, evaluate its contribution to breast cancer development and assess its value as a predictive marker of taxane sensitivity in breast cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-05
Application #
7890421
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$270,670
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Reese, Jordan M; Bruinsma, Elizabeth S; Nelson, Adam W et al. (2018) ER?-mediated induction of cystatins results in suppression of TGF? signaling and inhibition of triple-negative breast cancer metastasis. Proc Natl Acad Sci U S A 115:E9580-E9589
Lilyquist, Jenna; Ruddy, Kathryn J; Vachon, Celine M et al. (2018) Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. Cancer Epidemiol Biomarkers Prev 27:380-394
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Kannan, Nagarajan; Eaves, Connie J (2018) Macrophages stimulate mammary stem cells. Science 360:1401-1402
Guidugli, Lucia; Shimelis, Hermela; Masica, David L et al. (2018) Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. Am J Hum Genet 102:233-248
Kurmi, Kiran; Hitosugi, Sadae; Wiese, Elizabeth K et al. (2018) Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity. Cell Rep 22:1365-1373
Goetz, Matthew P; Sangkuhl, Katrin; Guchelaar, Henk-Jan et al. (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther 103:770-777
Baheti, Saurabh; Tang, Xiaojia; O'Brien, Daniel R et al. (2018) HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data. BMC Bioinformatics 19:271
Hart, Steven N; Hoskin, Tanya; Shimelis, Hermela et al. (2018) Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. Genet Med :
Ho, Ming-Fen; Correia, Cristina; Ingle, James N et al. (2018) Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. Biochem Pharmacol 152:279-292

Showing the most recent 10 out of 473 publications